OptiBiotix Health PLC SlimBiome® distribution agreement for Germany (3997X)

TIDMOPTI

RNS Number : 3997X

OptiBiotix Health PLC

19 December 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")

SlimBiome(R) distribution agreement for Germany

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces it has entered into an exclusive agreement with Draco Ingredients GmbH ("Draco") to distribute OptiBiotix's SlimBiome(R) proprietary weight management technology in Germany. Market exclusivity is linked to minimum order quantities in order to maximise the financial return for both parties.

Draco Ingredients (www.draco-ingredients.de) is a German food ingredient company established in 2001 focusing on the distribution of mainly dairy based ingredients to a broad spectrum of customers active in segments such as dairy, sports and medical nutrition.

This agreement is another step in extending the geographical reach and sales of SlimBiome(R). This is consistent with our strategy of increasing the number of geographies and applications SlimBiome(R) is used in as an ingredient. This builds revenue potential and brand recognition and reduces commercial risk.

Andre Wittke, General Manager of Draco Ingredients, commented: "We are delighted to have the opportunity of partnering with Optibiotix and look forward to building a presence for SlimBiome(R) in Germany by leveraging on the strengths of both organisations. We see SlimBiome's unique value proposition (patented solution backed by clinical and consumer studies and supported by EFSA-approved claims) as being a key driver of the sale of this functional ingredient to German customers in the near future."

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are pleased to announce this agreement with Draco Ingredients to service the German market. The timing of this agreement fits particularly well with our recent focus on creating the building-blocks necessary to accelerate and expand our reach to customers globally. This deal builds on the work done in 2019 to qualify multiple manufacturers of SlimBiome(R) in Europe and around the world (e.g Zeon: India, Agropur: USA) to de-risk our supply-chain in the case of a hard Brexit and give us access to one of Europe's largest economies."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                                 www.optibiotix.com 
 Stephen O'Hara, Chief Executive                     Contact via Walbrook 
                                                                    below 
 
 Cairn Financial Advisers LLP (NOMAD)                  Tel: [phone] 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 finnCap (Broker)                                      Tel: [phone] 
 Geoff Nash / Kate Bannatyne (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 goetzpartners securities Limited                      Tel: [phone] 
 Ulrich Kinzel 
 
 Walbrook PR Ltd                                       Mob: [phone] 
 Anna Dunphy 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCCKFDNFBDDOBD

(END) Dow Jones Newswires

December 19, 2019 02:00 ET (07:00 GMT)